Galapagos
- Country
- 🇧🇪Belgium
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 1.1K
- Market Cap
- $1.9B
- Website
- http://www.glpg.com
- Introduction
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in M...
Multiple Ascending Dose Study of GLPG0974 in Healthy Subjects
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 32
- Registration Number
- NCT01721980
- Locations
- 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium
Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 91
- Registration Number
- NCT01668641
- Locations
- 🇺🇦
State Institution 'Institute of Urgent and Recovery Surgery n.a. V.K. Gusaka' of AMS of Ukraine, Donetsk, Ukraine
🇷🇺State Healthcare Institution of city Moscow 'City Clinical Hospital #7', Moscow, Russian Federation
🇺🇦Institution of Therapy of AMS of Ukraine, Kharkiv, Ukraine
Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2013-03-28
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 36
- Registration Number
- NCT01665924
- Locations
- 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium
Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers
- First Posted Date
- 2012-04-19
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 12
- Registration Number
- NCT01580644
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium
GLPG0492 Pharmacodynamics
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 26
- Registration Number
- NCT01538420
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium
First-in-Human Exploratory Single Ascending Dose of GLPG0974
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 32
- Registration Number
- NCT01496937
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects
- First Posted Date
- 2011-08-19
- Last Posted Date
- 2012-08-15
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 16
- Registration Number
- NCT01419990
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium
Multiple Ascending Dose Study of GLPG0492 in Healthy Subjects
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 24
- Registration Number
- NCT01397370
- Locations
- 🇩🇪
Parexel Early Phase Clinical Unit, Berlin, Germany
Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2012-08-15
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 36
- Registration Number
- NCT01384422
- Locations
- 🇲🇩
Innophar MO S.R.L., Chisinau, Moldova, Republic of
GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic Study
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2011-10-18
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 45
- Registration Number
- NCT01336244
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium